CHL Medical Partners, Highland Capital Partners and Versant Ventures Lead
Round to Help Transform Clinical Microbiology
MADISON, Wis., Sept. 12 /PRNewswire/ -- OpGen, Inc., today announced that the company has raised $23.6 million in equity financing. The round was led by CHL Medical Partners, Highland Capital Partners and Versant Ventures, with previous investor Mason Wells also participating. In conjunction, CHL's Ron Lennox will become chairman of the Board of Directors and will also be joined on the board by Corey Mulloy and Bijan Salehizadeh from Highland, and Versant's Brian Atwood.
"We are delighted to partner with three top-tier venture firms to advance OpGen's efforts in the field of clinical microbiology, said Colin Dykes, Chief Scientific Officer of OpGen. "Each has a stellar track record and expertise in commercializing technologies for diagnostic and research applications, which will be critical as we continue to grow and expand our operations."
OpGen delivers breakthrough capabilities to identify microorganisms using a unique method to analyze DNA extracted directly from the microbial cells. "Optical Mapping" has been used by organizations worldwide for comparative genomic analysis of a range of organisms of importance to human health, including tracing the origins of food-poisoning cases such as the recent outbreak linked to contaminated spinach. With this new financing the company will develop commercial instrumentation systems for the clinical microbiology marketplace.
"Currently, clinical microbiology laboratories depend on isolating and
growing microorganisms from clinical samples," stated Ron Lennox. "This is
a lengthy process and provides only a simple taxonomic identification. The
results are rarely timely enough to influence choice of therapy and can
lead to excessive use of expensive broad-spectrum antibiotics. OpGen's new
system will provide data capable of identifying bacteria down to the strain
|SOURCE OpGen, Inc.|
Copyright©2007 PR Newswire.
All rights reserved